SG10201507362TA - Novel Regulatory Proteins And Inhibitors - Google Patents
Novel Regulatory Proteins And InhibitorsInfo
- Publication number
- SG10201507362TA SG10201507362TA SG10201507362TA SG10201507362TA SG10201507362TA SG 10201507362T A SG10201507362T A SG 10201507362TA SG 10201507362T A SG10201507362T A SG 10201507362TA SG 10201507362T A SG10201507362T A SG 10201507362TA SG 10201507362T A SG10201507362T A SG 10201507362TA
- Authority
- SG
- Singapore
- Prior art keywords
- inhibitors
- regulatory proteins
- novel regulatory
- novel
- proteins
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
- C07K14/4705—Regulators; Modulating activity stimulating, promoting or activating activity
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New breeds of animals
- A01K67/027—New breeds of vertebrates
- A01K67/0275—Genetically modified vertebrates, e.g. transgenic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0007—Nervous system antigens; Prions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6813—Hybridisation assays
- C12Q1/6827—Hybridisation assays for detection of mutation or polymorphism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6844—Nucleic acid amplification reactions
- C12Q1/686—Polymerase chain reaction [PCR]
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2207/00—Modified animals
- A01K2207/05—Animals modified by non-integrating nucleic acids, e.g. antisense, RNAi, morpholino, episomal vector, for non-therapeutic purpose
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
- A01K2217/054—Animals comprising random inserted nucleic acids (transgenic) inducing loss of function
- A01K2217/058—Animals comprising random inserted nucleic acids (transgenic) inducing loss of function due to expression of inhibitory nucleic acid, e.g. siRNA, antisense
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/15—Animals comprising multiple alterations of the genome, by transgenesis or homologous recombination, e.g. obtained by cross-breeding
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/20—Animal model comprising regulated expression system
- A01K2217/203—Animal model comprising inducible/conditional expression system, e.g. hormones, tet
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/105—Murine
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
- A01K2267/0306—Animal model for genetic diseases
- A01K2267/0312—Animal model for Alzheimer's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2814—Dementia; Cognitive disorders
- G01N2800/2821—Alzheimer
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US23146209P | 2009-08-05 | 2009-08-05 |
Publications (1)
Publication Number | Publication Date |
---|---|
SG10201507362TA true SG10201507362TA (en) | 2015-10-29 |
Family
ID=43544826
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG2012008215A SG178279A1 (en) | 2009-08-05 | 2010-08-05 | Novel regulatory proteins and inhibitors |
SG10201507362TA SG10201507362TA (en) | 2009-08-05 | 2010-08-05 | Novel Regulatory Proteins And Inhibitors |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG2012008215A SG178279A1 (en) | 2009-08-05 | 2010-08-05 | Novel regulatory proteins and inhibitors |
Country Status (5)
Country | Link |
---|---|
US (1) | US9605041B2 (en) |
EP (1) | EP2461673A4 (en) |
JP (2) | JP6166534B2 (en) |
SG (2) | SG178279A1 (en) |
WO (1) | WO2011016861A2 (en) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2434895A4 (en) | 2009-05-13 | 2013-08-07 | Intra Cellular Therapies Inc | Organic compounds |
MX352749B (en) | 2011-11-01 | 2017-12-06 | Modgene Llc | Compositions and methods for reduction of amyloid-beta load. |
JP2015515282A (en) * | 2012-04-25 | 2015-05-28 | エムユーエスシー ファウンデーション フォー リサーチ ディベロップメント | Compositions and methods for wound healing and tissue repair |
US9801882B2 (en) | 2013-02-17 | 2017-10-31 | Intra-Cellular Therapies, Inc. | Phosphodiesterase-1 inhibitors and their use in treatment of cardiovascular diseases |
KR102234112B1 (en) * | 2014-06-27 | 2021-04-02 | 한양대학교 산학협력단 | Brain Specific Nuecleic Acid delivery |
WO2016022893A1 (en) | 2014-08-07 | 2016-02-11 | Intra-Cellular Therapies, Inc. | Organic compounds |
US10285992B2 (en) | 2014-08-07 | 2019-05-14 | Intra-Cellular Therapies, Inc. | Combinations of PDE1 inhibitors and NEP inhibitors and associated methods |
US10682354B2 (en) | 2016-03-28 | 2020-06-16 | Intra-Cellular Therapies, Inc. | Compositions and methods |
JP6994715B2 (en) * | 2017-10-04 | 2022-02-04 | 国立大学法人京都大学 | Molecular probe for Bcr-Abl protein imaging |
EP3746081A4 (en) | 2018-01-31 | 2021-10-27 | Intra-Cellular Therapies, Inc. | Novel uses |
Family Cites Families (102)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS6032638B2 (en) | 1976-09-01 | 1985-07-29 | 武田薬品工業株式会社 | 3-Aminopyrazolo[3,4-d]pyrimidine derivative |
JPS58500966A (en) | 1981-04-22 | 1983-06-09 | ビイク グルデン ロンベルク ヒエ−ミツシエ フアブリ−ク ゲゼルシヤフト ミツト ベシユレンクテル ハフツング | New pyrazolo[3,4-d]pyrimidine, its production method, and pharmaceuticals containing the same |
HU186891B (en) | 1981-06-12 | 1985-10-28 | Richter Gedeon Vegyeszet | Process for producing esters of apovincaminic acid |
US4666908A (en) | 1985-04-05 | 1987-05-19 | Warner-Lambert Company | 5-Substituted pyrazolo[4,3-d]pyrimidine-7-ones and methods of use |
US5385915A (en) | 1990-05-16 | 1995-01-31 | The Rockefeller University | Treatment of amyloidosis associated with Alzheimer disease using modulators of protein phosphorylation |
US5250534A (en) | 1990-06-20 | 1993-10-05 | Pfizer Inc. | Pyrazolopyrimidinone antianginal agents |
NZ238609A (en) | 1990-06-21 | 1993-12-23 | Schering Corp | Polycyclic guanine derivatives; preparation, pharmaceutical compositions, |
US5272055A (en) | 1991-12-24 | 1993-12-21 | The University Of Kentucky Research Foundation | Detection of Alzheimer's disease and other diseases using a photoaffinity labeling method |
US5294612A (en) | 1992-03-30 | 1994-03-15 | Sterling Winthrop Inc. | 6-heterocyclyl pyrazolo [3,4-d]pyrimidin-4-ones and compositions and method of use thereof |
US5521184A (en) | 1992-04-03 | 1996-05-28 | Ciba-Geigy Corporation | Pyrimidine derivatives and processes for the preparation thereof |
US20020006963A1 (en) | 1992-06-23 | 2002-01-17 | Young James W. | Method of using and compositions comprising (-) sibutramine optionally in combination with other pharmacologically active compounds |
AU681875B2 (en) | 1993-02-26 | 1997-09-11 | Schering Corporation | 2-benzyl-polycyclic guanine derivatives and process for preparing them |
GB9304919D0 (en) | 1993-03-10 | 1993-04-28 | Celltech Ltd | Chemical compounds |
US5543520A (en) | 1993-10-01 | 1996-08-06 | Ciba-Geigy Corporation | Pyrimidine derivatives |
BR9407799A (en) | 1993-10-12 | 1997-05-06 | Du Pont Merck Pharma | Composition of matter treatment method and pharmaceutical composition |
US5620981A (en) | 1995-05-03 | 1997-04-15 | Warner-Lambert Company | Pyrido [2,3-D]pyrimidines for inhibiting protein tyrosine kinase mediated cellular proliferation |
IL117923A (en) | 1995-05-03 | 2000-06-01 | Warner Lambert Co | Anti-cancer pharmaceutical compositions containing polysubstituted pyrido¬2,3-d¾pyrimidine derivatives and certain such novel compounds |
US5744346A (en) | 1995-06-07 | 1998-04-28 | Athena Neurosciences, Inc. | β-secretase |
GB9523675D0 (en) | 1995-11-20 | 1996-01-24 | Celltech Therapeutics Ltd | Chemical compounds |
US5824683A (en) | 1995-11-28 | 1998-10-20 | Schering Corporation | 2'- 4'-halo- 1,1'-biphenyl!-4-yl!methyl!-5'-methyl-spiro cyclopentane-1,7' (8'H)- 3H! imidazo 2,1-b!purin!-4' (5'H)-ones |
GB9526245D0 (en) | 1995-12-21 | 1996-02-21 | Celltech Therapeutics Ltd | Chemical compounds |
US5798246A (en) | 1996-03-25 | 1998-08-25 | Incyte Pharmaceuticals, Inc. | Cyclic nucleotide phosphodiesterase |
US5777195A (en) | 1996-05-17 | 1998-07-07 | The Rockefeller University | Knockout mutant mouse for DARPP-32 and use thereof |
GB9610964D0 (en) | 1996-05-24 | 1996-07-31 | Pharmacia & Upjohn Spa | Substituted tetralylmethylen-oxindole analogues as tyrosine kinase inhibitors |
JPH1143499A (en) | 1996-09-11 | 1999-02-16 | Takeda Chem Ind Ltd | New protein and its dna |
US5885834A (en) | 1996-09-30 | 1999-03-23 | Epstein; Paul M. | Antisense oligodeoxynucleotide against phosphodiesterase |
GB9622363D0 (en) | 1996-10-28 | 1997-01-08 | Celltech Therapeutics Ltd | Chemical compounds |
WO1998028281A1 (en) | 1996-12-23 | 1998-07-02 | Celltech Therapeutics Limited | Fused polycyclic 2-aminopyrimidine derivatives, their preparation and their use as protein tyrosine kinase inhibitors |
AU742388B2 (en) | 1996-12-24 | 2002-01-03 | Chugai Seiyaku Kabushiki Kaisha | Aromatic amine derivatives having nos inhibiting action |
SE9701398D0 (en) | 1997-04-15 | 1997-04-15 | Astra Pharma Prod | Novel compounds |
IT1291372B1 (en) | 1997-05-21 | 1999-01-07 | Schering Plough S P A | USE OF HETEROCYCLIC ANALOGS OF 1,2,4-TRIAZOLE (1,5-C) PYRIMIDINS FOR THE PREPARATION OF MEDICATIONS USEFUL FOR THE TREATMENT OF DISEASES |
US6103737A (en) | 1997-07-03 | 2000-08-15 | Dupont Pharmaceuticals Company | Aryl- and arylamino- substituted heterocycles as corticotropin releasing hormone antagonists |
US6440965B1 (en) | 1997-10-15 | 2002-08-27 | Krenitsky Pharmaceuticals, Inc. | Substituted pyrimidine derivatives, their preparation and their use in the treatment of neurodegenerative or neurological disorders of the central nervous system |
US6013621A (en) | 1997-10-17 | 2000-01-11 | The Rockfeller University | Method of treating psychosis and/or hyperactivity |
WO1999020273A1 (en) | 1997-10-17 | 1999-04-29 | The Rockefeller University | Use of an inhibitor of the dephosphorylation of darpp-32 for treating schizophrenia |
GB9722520D0 (en) | 1997-10-24 | 1997-12-24 | Pfizer Ltd | Compounds |
CA2326324C (en) | 1998-03-31 | 2010-05-11 | Kyowa Hakko Kogyo Co., Ltd. | Nitrogen-containing heterocyclic compound |
US6133273A (en) | 1998-05-08 | 2000-10-17 | American Home Products Corporation | Pyrazolopyrimidine-2,4-dione sulfonamides |
PE20000728A1 (en) | 1998-06-26 | 2000-08-21 | Cocensys Inc | HETEROCYCLES 4-BENZYL PIPERIDINE ALKYLSULFOXIDE AND THEIR USE AS SUBTYPE-SELECTIVE NMDA RECEPTOR ANTAGONISTS |
KR100640265B1 (en) | 1998-09-17 | 2006-10-31 | 오츠카 세이야쿠 가부시키가이샤 | Ly6h gene |
US6699671B1 (en) | 1998-09-24 | 2004-03-02 | Pharmacia & Upjohn Company | Alzheimer's disease secretase, APP substrates therefor, and uses therefor |
JP2000224992A (en) | 1998-11-30 | 2000-08-15 | Tanabe Seiyaku Co Ltd | New phosphodiesterase and gene coding for the same |
GB9907658D0 (en) | 1999-04-06 | 1999-05-26 | Zeneca Ltd | Chemical compounds |
EP1190070A1 (en) | 1999-06-25 | 2002-03-27 | Memory Pharmaceutical Corporation | Cyclic amp phosphodiesterase isoforms and methods of use |
EP1206265B1 (en) | 1999-06-30 | 2003-11-12 | Merck & Co., Inc. | Src kinase inhibitor compounds |
JP2003503354A (en) | 1999-06-30 | 2003-01-28 | メルク エンド カムパニー インコーポレーテッド | SRC kinase inhibitor compounds |
DE19931206A1 (en) | 1999-07-07 | 2001-01-11 | Stief Christian | Relaxing, or increasing cyclic adenosine monophosphate concentration in smooth muscular tissue, e.g. by administration of cAMP phosphodiesterase inhibitors, dipyridamole or sildenafil |
KR20020027635A (en) | 1999-09-10 | 2002-04-13 | 폴락 돈나 엘. | Tyrosine kinase inhibitors |
WO2001021219A2 (en) * | 1999-09-21 | 2001-03-29 | The Government Of The United States Of America, As Represented By The Secretary Of Health And Human Services | Imaging of drug accumulation as a guide to antitumor therapy |
CZ20021067A3 (en) | 1999-09-30 | 2002-11-13 | Neurogen Corporation | Certain alkylenediamine substituted pyrazolo[1,5-a]- 1,5-pyrimidines and pyrazolo[1,5-a]-1,3,5-triazines |
US20020147197A1 (en) | 1999-10-08 | 2002-10-10 | Newman Michael J. | Methods and compositions for enhancing pharmaceutical treatments |
JP2003511452A (en) | 1999-10-11 | 2003-03-25 | ファイザー・インク | 5- (2-Substituted-5-heterocyclylsulfonylpyrid-3-yl) -dihydropyrazolo [4,3-d] pyrimidin-7-ones as phosphodiesterase inhibitors |
IL139073A0 (en) | 1999-10-21 | 2001-11-25 | Pfizer | Treatment of neuropathy |
AU2005201482A1 (en) | 1999-11-08 | 2005-05-05 | Pfizer Inc. | Compounds for the treatment of female sexual dysfunction |
SE9904724D0 (en) | 1999-12-22 | 1999-12-22 | Carlsson A Research Ab | New modulators of dopamine neurotransmission I |
WO2001056567A1 (en) | 2000-02-04 | 2001-08-09 | Novo Nordisk A/S | 2,4-diaminothiazole derivatives and their use as glycogen synthase kinase-3 (gsk-3) inhibitors |
US7087608B2 (en) | 2000-03-03 | 2006-08-08 | Robert Charles Atkins | Use of PDGF receptor tyrosine kinase inhibitors for the treatment of diabetic nephropathy |
US6333167B1 (en) | 2000-03-10 | 2001-12-25 | American Home Products Corp. | Methods and reagents for identifying inhibitors of proteolysis of membrane-associated proteins |
EP1136485A1 (en) | 2000-03-23 | 2001-09-26 | Sanofi-Synthelabo | Aminophenyl pyrimidone derivatives |
MXPA02009756A (en) | 2000-04-03 | 2003-06-17 | Bristol Myers Squibb Co | Isolation of functionally active gamma secretase protein complex and methods for detection of activity and inhibitors thereof. |
US6632812B2 (en) | 2000-04-11 | 2003-10-14 | Dupont Pharmaceuticals Company | Substituted lactams as inhibitors of Aβ protein production |
JP2003530437A (en) | 2000-04-13 | 2003-10-14 | マヨ ファウンデーション フォー メディカル エデュケーション アンド リサーチ | Aβ42 lowering substance |
CA2407031A1 (en) | 2000-04-19 | 2001-10-25 | Lilly Icos Llc | Use of cyclic gmp-specific phosphodiesterase inhibitors for treatment of parkinson's disease |
WO2001085924A2 (en) | 2000-05-11 | 2001-11-15 | Scios Inc. | MODULATION OF η-SECRETASE ACTIVITY |
MY128450A (en) | 2000-05-24 | 2007-02-28 | Upjohn Co | 1-(pyrrolidin-1-ylmethyl)-3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives |
US6693099B2 (en) | 2000-10-17 | 2004-02-17 | The Procter & Gamble Company | Substituted piperazine compounds optionally containing a quinolyl moiety for treating multidrug resistance |
SE0102315D0 (en) | 2001-06-28 | 2001-06-28 | Astrazeneca Ab | Compounds |
US7320785B2 (en) | 2001-08-10 | 2008-01-22 | The Rockefeller University | Compositions and methods for modulation of DARPP-32 phosphorylation |
US6969719B2 (en) | 2001-08-28 | 2005-11-29 | Schering Corporation | Polycyclic guanine phosphodiesterase V inhibitors |
US20030211040A1 (en) | 2001-08-31 | 2003-11-13 | Paul Greengard | Phosphodiesterase activity and regulation of phosphodiesterase 1B-mediated signaling in brain |
US6649908B2 (en) | 2001-09-20 | 2003-11-18 | Agilent Technologies, Inc. | Multiplexing capillary array for atmospheric pressure ionization-mass spectrometry |
US20030195205A1 (en) | 2001-11-02 | 2003-10-16 | Pfizer Inc. | PDE9 inhibitors for treating cardiovascular disorders |
HN2002000317A (en) | 2001-11-02 | 2003-05-21 | Pfizer | PDE9 INHIBITORS FOR TREATMENT OF CARDIOVASCULAR DISORDERS |
IL161155A0 (en) | 2001-11-02 | 2004-08-31 | Pfizer Prod Inc | Treatment of insulin resistance syndrome and type 2 diabetes with pde9 inhibitors |
MXPA04004370A (en) | 2001-11-09 | 2004-08-11 | Schering Corp | Polycyclic guanine derivative phosphodiesterase v inhibitors. |
WO2003057165A2 (en) | 2002-01-04 | 2003-07-17 | The Rockefeller University | COMPOSITIONS AND METHODS FOR PREVENTION AND TREATMENT OF AMYLOID-β PEPTIDE-RELATED DISORDERS |
US7579324B2 (en) | 2002-02-15 | 2009-08-25 | C-A-I-R Biosciences Gmbh | Conjugates of biologically active compounds, methods for their preparation and use, formulation and pharmaceutical applications thereof |
WO2003072801A2 (en) | 2002-02-21 | 2003-09-04 | The Rockefeller University | Compositions and method for regulation of calcium-dependent signalling in brain |
RU2315043C2 (en) | 2002-06-28 | 2008-01-20 | Ниппон Синяку Ко., Лтд. | Amide derivative, pharmaceutical composition and therapeutic agents based on thereof |
GB0215676D0 (en) | 2002-07-05 | 2002-08-14 | Novartis Ag | Organic compounds |
SE0203825D0 (en) | 2002-12-20 | 2002-12-20 | Astrazeneca Ab | Novel fused heterocycles and uses thereof |
EP1583820A4 (en) * | 2003-01-14 | 2007-07-18 | Bristol Myers Squibb Co | Polynucleotides and polypeptides associated with the nf-kb pathway |
US20050048573A1 (en) | 2003-02-03 | 2005-03-03 | Plexxikon, Inc. | PDE5A crystal structure and uses |
WO2004087906A1 (en) | 2003-03-31 | 2004-10-14 | Pfizer Products Inc. | Crystal structure of 3',5'-cyclic nucleotide phosphodiesterase 1b (pde1b) and uses thereof |
EP1624893A2 (en) | 2003-04-01 | 2006-02-15 | Applied Research Systems ARS Holding N.V. | Inhibitors of phosphodiesterases in infertility |
PL1635835T3 (en) | 2003-06-13 | 2010-06-30 | Novartis Ag | 2-aminopyrimidine derivatives as raf kinase inhibitors |
WO2005019258A2 (en) * | 2003-08-11 | 2005-03-03 | Genentech, Inc. | Compositions and methods for the treatment of immune related diseases |
GB0325031D0 (en) | 2003-10-27 | 2003-12-03 | Novartis Ag | Organic compounds |
CA2554201C (en) | 2004-01-21 | 2015-04-14 | Emory University | Compositions and use of tyrosine kinase inhibitors to treat pathogenic infection |
AU2006255028B2 (en) | 2005-06-06 | 2012-04-19 | Intra-Cellular Therapies, Inc. | Organic compounds |
GB0512091D0 (en) * | 2005-06-14 | 2005-07-20 | Novartis Ag | Organic compounds |
US20080194592A1 (en) | 2005-08-23 | 2008-08-14 | Intra-Cellular Therapies, Inc. | Organic Compounds |
EP2023729B1 (en) | 2006-06-06 | 2016-05-04 | Intra-Cellular Therapies, Inc. | Organic compounds |
WO2008055959A1 (en) | 2006-11-09 | 2008-05-15 | Galapagos N.V. | Novel compounds useful for the treatment of degenerative & inflammatory diseases |
WO2008057599A2 (en) | 2006-11-10 | 2008-05-15 | Intra-Cellular Therapies, Inc. | Methods for the treatment of abeta related disorders and compositions therefor |
EP2081431B1 (en) | 2006-11-13 | 2013-01-16 | Intra-Cellular Therapies, Inc. | Organic compounds |
US9006258B2 (en) | 2006-12-05 | 2015-04-14 | Intra-Cellular Therapies, Inc. | Method of treating female sexual dysfunction with a PDE1 inhibitor |
WO2008153959A1 (en) | 2007-06-07 | 2008-12-18 | Intra-Cellular Therapies, Inc. | Novel heterocycle compounds and uses thereof |
WO2008153974A1 (en) * | 2007-06-07 | 2008-12-18 | Intra-Cellular Therapies, Inc. | Novel heterocycle compounds and uses thereof |
AU2008335811B2 (en) | 2007-12-06 | 2012-05-17 | Intra-Cellular Therapies, Inc. | Organic compounds |
WO2009073210A1 (en) | 2007-12-06 | 2009-06-11 | Intra-Cellular Therapies, Inc | Organic compounds |
EP2434895A4 (en) | 2009-05-13 | 2013-08-07 | Intra Cellular Therapies Inc | Organic compounds |
-
2010
- 2010-08-05 SG SG2012008215A patent/SG178279A1/en unknown
- 2010-08-05 JP JP2012523606A patent/JP6166534B2/en not_active Expired - Fee Related
- 2010-08-05 WO PCT/US2010/002173 patent/WO2011016861A2/en active Application Filing
- 2010-08-05 SG SG10201507362TA patent/SG10201507362TA/en unknown
- 2010-08-05 EP EP10806753.9A patent/EP2461673A4/en not_active Withdrawn
-
2012
- 2012-02-06 US US13/367,049 patent/US9605041B2/en active Active
-
2015
- 2015-11-06 JP JP2015218065A patent/JP2016102110A/en active Pending
Also Published As
Publication number | Publication date |
---|---|
EP2461673A2 (en) | 2012-06-13 |
EP2461673A4 (en) | 2013-08-07 |
US9605041B2 (en) | 2017-03-28 |
JP2016102110A (en) | 2016-06-02 |
WO2011016861A2 (en) | 2011-02-10 |
JP6166534B2 (en) | 2017-07-19 |
SG178279A1 (en) | 2012-03-29 |
US20130149309A1 (en) | 2013-06-13 |
JP2013500741A (en) | 2013-01-10 |
WO2011016861A3 (en) | 2012-08-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1218558A1 (en) | Mirac proteins mirac | |
IL222961A0 (en) | Novel dna-dinding proteins and uses thereof | |
IL218678A0 (en) | Protein kinase conjugates and inhibitors | |
HK1189587A1 (en) | Bromodomain inhibitors and uses thereof | |
EP2606031A4 (en) | Autotaxin inhibitors and uses thereof | |
IL218778A0 (en) | Lysine specific demethylase - 1 inhibitors and their use | |
SG10201507362TA (en) | Novel Regulatory Proteins And Inhibitors | |
EP2387572A4 (en) | Protein kinase c inhibitors and uses thereof | |
EP2637502A4 (en) | Mutant-selective egfr inhibitors and uses thereof | |
GB201004178D0 (en) | Enzyme inhibitors | |
EP2467382A4 (en) | Amino tetrahydro-pyridopyrimidine pde10 inhibitors | |
EP2612913A4 (en) | Novel hydrolase protein | |
EP2556055A4 (en) | Ship inhibitors and uses thereof | |
IL240134A0 (en) | Novel proteins | |
ZA201109283B (en) | Protein | |
SG10201408577SA (en) | Protein display | |
EP2639302A4 (en) | Modified fluorescent protein | |
IL214333A0 (en) | Carbamoylphosphonates as inhibitors and uses thereof | |
IL216594A0 (en) | Proteasome inhibitors and uses thereof | |
GB0909384D0 (en) | Protein | |
GB0915927D0 (en) | Novel inhibitors | |
GB0903650D0 (en) | Glyoalase inhibitors | |
GB0902661D0 (en) | Inhibitors | |
GB0902222D0 (en) | Protein expression | |
GB201006605D0 (en) | Novel inhibitors |